» Articles » PMID: 26686572

Glyceradehyde-3-phosphate Dehydrogenase As a Suitable Vaccine Candidate for Protection Against Bacterial and Parasitic Diseases

Overview
Journal Vaccine
Date 2015 Dec 22
PMID 26686572
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The enzyme glyceraldehyde-3-P-dehydrogenase (GAPDH) has been identified as having other properties in addition to its key role in glycolysis. The ability of GAPDH to bind to numerous extracellular matrices, modulation of host-immune responses, a role in virulence and surface location has prompted numerous investigators to postulate that GAPDH may be a good vaccine candidate for protection against numerous pathogens. Although immune responses against GAPDH have been described for many microorganisms, vaccines containing GAPDH have been successfully tested in few cases including those against the trematode-Schistosoma mansoni, the helminth-Enchinococcus multilocularis; the nematode filaria- Litomosoides sigmodontis; fish pathogens such as Aeromonas spp., Vibrio spp., Edwarsiella spp., and Streptococcus iniae; and environmental streptococci, namely, Streptococcus uberis and Streptococcus dysgalactiae. Before GAPDH-based vaccines are considered viable options for protection against numerous pathogens, we need to take into account the homology between the host and pathogen GAPDH proteins to prevent potential autoimmune reactions, thus protective GAPDH epitopes unique to the pathogen protein must be identified.

Citing Articles

Exploring the exoproteome of the parasitic nematode (s. s.) and its impact on the human host - an cross-talk proteomic approach.

Stryinski R, Fiedorowicz E, Mateos J, Andronowska A, Lopienska-Biernat E, Carrera M Front Immunol. 2025; 16:1509984.

PMID: 39963139 PMC: 11830668. DOI: 10.3389/fimmu.2025.1509984.


Unbiased phage display screening identifies hidden malaria vaccine targets.

Jacobs-Lorena M, Cha S Emerg Microbes Infect. 2024; 13(1):2429617.

PMID: 39529575 PMC: 11587725. DOI: 10.1080/22221751.2024.2429617.


Therapeutic and vaccinomic potential of moonlighting proteins for the discovery and design of drugs and vaccines against schistosomiasis.

Motlhatlhedi K, Pilusa N, Ndaba T, George M, Masamba P, Kappo A Am J Transl Res. 2024; 16(9):4279-4300.

PMID: 39398578 PMC: 11470331. DOI: 10.62347/BXRT7210.


Targeting Life Cycle with Novel Parasite Ligands as Vaccine Antigens.

Khan S, Patel M, Patni A, Cha S Vaccines (Basel). 2024; 12(5).

PMID: 38793735 PMC: 11125637. DOI: 10.3390/vaccines12050484.


Alterations in cell arrangements of group B streptococcus due to virulence factor expression can bias estimates of bacterial populations based on colony count measures.

Thapa R, Goh K, Desai D, Copeman E, Acharya D, Sullivan M Microbiology (Reading). 2024; 170(4).

PMID: 38656296 PMC: 11084685. DOI: 10.1099/mic.0.001453.